{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=19", "query": { "condition": "Neuroendocrine Tumor of the Lung", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 543, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T19:43:24.848Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "PLN-101095", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pliant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2023-08-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270706" }, { "nct_id": "NCT04551885", "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT516", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-09-07", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551885" }, { "nct_id": "NCT01307267", "title": "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Renal Cell", "Carcinoma, Squamous Cell of Head and Neck", "Malignant Melanoma" ], "interventions": [ { "name": "PF-05082566", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2011-06-21", "completion_date": "2019-02-20", "has_results": true, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 35, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307267" }, { "nct_id": "NCT02900248", "title": "CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neoplasms", "Lung Neoplasms", "Colon Neoplasms", "Breast Neoplasms", "Pancreatic Neoplasms", "Prostate Neoplasms", "Kidney Neoplasms", "Liver Neoplasms", "Rectal Neoplasms", "Hematologic Neoplasms", "Multiple Myeloma", "Myelodysplastic Syndromes", "Ovarian Neoplasms", "Bladder Neoplasms", "Testicular Neoplasms", "Endometrial Neoplasms", "Brain Neoplasms", "Biliary Tract Neoplasms", "Head and Neck Neoplasms", "Uterine Cervical Neoplasms", "Skin Neoplasms", "Melanoma", "Gastric Neoplasms", "Anal Neoplasms", "Sarcoma" ], "interventions": [ { "name": "Provider determined", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "CureOne", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-10-02", "completion_date": "2019-03-29", "has_results": false, "last_update_posted_date": "2019-04-02", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 1, "location_summary": "Idaho Falls, Idaho", "locations": [ { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT02900248" }, { "nct_id": "NCT01773655", "title": "Clinical and Histopathologic Characteristics of BAP1 Mutations", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Pleural Mesothelioma (MPM)", "Choroidal Nevus", "Primary Uveal Melanoma (UM)", "Metastatic Uveal Melanoma (UM)", "Renal Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "tumor specimens", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2013-01", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 2, "location_summary": "Harrison, New York • New York, New York", "locations": [ { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773655" }, { "nct_id": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC", "Malignant Melanoma", "Sarcoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 23, "start_date": "2022-11-17", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130255" }, { "nct_id": "NCT05709821", "title": "IMM60 and Pembrolizumab in Melanoma and NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "IMM60", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iOx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-11-15", "completion_date": "2024-04-22", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05709821" }, { "nct_id": "NCT05969860", "title": "At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Anal Carcinoma", "Advanced Biliary Tract Carcinoma", "Advanced Bladder Carcinoma", "Advanced Breast Carcinoma", "Advanced Carcinoid Tumor", "Advanced Cervical Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastric Carcinoma", "Advanced Glioblastoma", "Advanced Head and Neck Carcinoma", "Advanced HER2 Positive Breast Carcinoma", "Advanced Lung Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Germ Cell Tumor", "Advanced Malignant Solid Neoplasm", "Advanced Neuroendocrine Carcinoma", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Prostate Small Cell Neuroendocrine Carcinoma", "Advanced Prostate Carcinoma", "Hematopoietic and Lymphoid System Neoplasm", "Multiple Myeloma", "Myelodysplastic Syndrome", "Advanced Basal Cell Carcinoma", "Advanced Cholangiocarcinoma", "Advanced Endometrial Carcinoma", "Advanced Esophageal Carcinoma", "Advanced Fallopian Tube Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Liver Carcinoma", "Advanced Lymphoma", "Advanced Malignant Testicular Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Penile Carcinoma", "Advanced Primary Malignant Central Nervous System Neoplasm", "Advanced Renal Cell Carcinoma", "Advanced Sarcoma", "Advanced Skin Squamous Cell Carcinoma", "Advanced Urethral Carcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Advanced Appendix Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Clinical Encounter", "type": "PROCEDURE" }, { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-08-23", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Grand Forks, North Dakota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05969860" }, { "nct_id": "NCT06075524", "title": "Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Lung Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2015-06-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075524" }, { "nct_id": "NCT02387125", "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Non-small Cell Lung Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CMB305", "type": "BIOLOGICAL" }, { "name": "G100", "type": "BIOLOGICAL" }, { "name": "Metronomic CPA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 79, "start_date": "2015-02-28", "completion_date": "2019-03-29", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-15T19:43:24.848Z", "location_count": 8, "location_summary": "Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387125" } ] }